natgillin/translations-raw huggingface dataset:
Placebo 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept Antal patienter 324 
Week 52 Placebo 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept
Tag plasthætten af hætteglasset. 
Remove the plastic cap from the vial.
PsA-studie 2 
PsA study 2
Den aftagelige hætte på Cosentyx fyldt pen indeholder et derivat af naturgummilatex. 
The removable cap of the Cosentyx pre-filled pen contains a derivative of natural rubber latex.
Vigtigt sikkerhedstjek, før du foretager indsprøjtningen: Væsken skal være klar. 
Important safety checks before you inject:
For en sikkerheds skyld bør Cosentyx undgås under graviditet. 
As a precautionary measure, it is preferable to avoid the use of Cosentyx during pregnancy.
Injektionsvæske, opløsning, i fyldt pen (SensoReady pen) 
Solution for injection in pre-filled pen (SensoReady pen)
Indlægssedlen indeholder detaljerede brugsanvisninger. 
Detailed instructions for use are provided in the package leaflet.
Fordelen ved at bruge Cosentyx til psoriasisgigt er, at det mindsker tegn og symptomer på sygdommen, forsinker skader på leddenes brusk og knogle samt forbedrer din evne til at udføre sædvanlige daglige aktiviteter. 
Using Cosentyx in psoriatic arthritis will benefit you by reducing the signs and symptoms of the disease, slowing down the damage to the cartilage and bone of the joints and improving your ability to do normal daily activities.
Pakning indeholder 1 fyldt pen 
Pack containing 1 pre-filled pen
Cosentyx leveres i en fyldt 1 ml glassprøjte med en silikone-coatet bromobutyl-gummistempelprop, fast 27G x ½" kanyle og fast kanyleskjold af styrenbutadiengummi samlet i en passiv sikkerhedsenhed af polycarbonat. 
Cosentyx is supplied in a pre-filled 1 ml glass syringe with a silicone-coated bromobutyl rubber plunger stopper, staked 27G x ½″ needle and rigid needle shield of styrene butadiene rubber assembled in a passive safety device of polycarbonate.
Af de 72 patienter i AS-studie 2, der initialt var randomiseret til secukinumab 150 mg, var 61 (84,7 %) stadig i behandling ved uge 52. 
In AS study 2, among 72 patients initially randomised to secukinumab 150 mg, 61 (84.7%) patients were still on treatment at week 52.
I AS-studie 1 og -studie 2 viste patienter, der blev behandlet med secukinumab 150 mg, forbedringer i helbredsrelateret livskvalitet målt ved ASQoL (p=0,001) og SF-36 Physical Component Summary (SF36 PCS) (p<0,001). 
In AS study 1 and study 2, patients treated with secukinumab 150 mg showed improvements in healthrelated quality of life as measured by AS Quality of Life Questionnaire (ASQoL) (p=0.001) and SF-36 Physical Component Summary (SF-36PCS) (p<0.001).
PsA-studie 2 (FUTURE 2) evaluerede 397 patienter, hvoraf 46,6 % fik samtidig MTX. 
PsA study 2 (FUTURE 2) evaluated 397 patients, of whom 46.6% had concomitant MTX.
I GESTURE-studiet var secukinumab superior i forhold til placebo ved uge 16 (33,3% for 300 mg, 22,1% for 150 mg og 1,5% for placebo), vurderet ud fra en signifikant forbedring i ppIGA 0 eller 1-respons (”clear” eller ”almost clear”), hos patienter med moderat til svær palmoplantar plaque psoriasis. 
In the GESTURE study, secukinumab was superior to placebo at week 16 (33.3% for 300 mg, 22.1% for 150 mg, and 1.5% for placebo) as assessed by significant improvement of ppIGA 0 or 1 response (“clear” or “almost clear”) for patients with moderate to severe palmoplantar plaque psoriasis.
Cosentyx leveres i en pakning med ét hætteglas. 
Cosentyx is supplied in a pack containing one vial.
(næsesvælgkatar, forkølelse) 
(nasopharyngitis, rhinitis)
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Cosentyx hos pædiatriske patienter fra fødsel til under 6 år med plaque psoriasis og hos pædiatriske patienter fra fødsel til under 2 år med kronisk idiopatisk artritis (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with Cosentyx in plaque psoriasis in paediatric patients aged from birth to less than 6 years and in chronic idiopathic arthritis for paediatric patients aged from birth to less than 2 years (see section 4.2 for information on paediatric use).
Du kan finde detaljerede oplysninger om, hvordan du indsprøjter Cosentyx, i afsnittet ”Anvisninger til brug af Cosentyx SensoReady-pen” sidst i denne indlægsseddel. 
For detailed instructions on how to inject Cosentyx, see “Instructions for use of the Cosentyx SensoReady pen” at the end of this leaflet.
Opløsningen er klar og farveløs til let gul. 
The solution is clear and colourless to slightly yellow.
I AS-studie 2 medførte behandling med secukinumab 150 mg en større forbedring i målene for sygdomsaktivitet sammenlignet med placebo ved uge 16 (se tabel 7). 
In AS study 2, treatment with secukinumab 150 mg resulted in greater improvement in measures of disease activity compared with placebo at week 16 (see Table 7).
PsA-studie 1 (FUTURE 1) evaluerede 606 patienter, hvoraf 60,7 % fik samtidig MTX. 
PsA study 1 (FUTURE 1) evaluated 606 patients, of whom 60.7% had concomitant MTX.
Antal patienter PASI 50-respons n (%) 
Number of patients PASI 50 response n (%)
I kliniske studier vedrørende psoriasis, psoriasisartrit og ankyloserende spondylitis udviklede under 1 % af de patienter, der blev behandlet med secukinumab i op til 52 uger, udviklede antistoffer over for secukinumab. 
In psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies, less than 1% of patients treated with secukinumab developed antibodies to secukinumab up to 52 weeks of treatment.
PsA-studie 1 
PsA study 1
Cosentyx bruges til at behandle en sygdom, der hedder ankyloserende spondylitis. 
Cosentyx is used to treat a condition called “ankylosing spondylitis”.
PsA-studie 3 
PsA study 3
Indeholder også: Trehalosedihydrat, histidin, histidinhydrochloridmonohydrat, methionin, polysorbat 80, vand til injektionsvæsker. 
Also contains: Trehalose dihydrate, histidine, histidine hydrochloride monohydrate, methionine, polysorbate 80, water for injections.
Til patienter med samtidig moderat til svær plaque psoriasis, eller som responderede utilstrækkeligt på anti-TNFα, er den anbefalede dosis 300 mg s.c. med initial dosering uge 0, 1, 2, 3 og 4 efterfulgt af månedlig vedligeholdelsesdosering. 
For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders (IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
Hvis du ikke får det bedre af disse lægemidler, vil du få Cosentyx for at mindske tegn og symptomer på sygdommen, mindske betændelsesreaktionen og forbedre din fysiske funktion. 
If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of the disease, reduce inflammation and improve your physical function.
• efter den udløbsdato, der står på pakningen eller på etiketten på pennen efter EXP. 
• after the expiry date which is stated on the outer box or the label on the pen after “EXP”.
Injektionssprøjten skal tages ud af køleskabet 20 minutter før injektion, så det kan opnå rumtemperatur. 
The syringe should be taken out of the refrigerator 20 minutes before injecting to allow it to reach room temperature.
Pennen skal tages ud af køleskabet 20 minutter før injektion, så det kan opnå rumtemperatur. 
The pen should be taken out of the refrigerator 20 minutes before injecting to allow it to reach room temperature.
• alvorlig hudkløe med rødt udslæt og knopper. 
• severe itching of the skin, with a red rash or raised bumps.
• Kanyleboks til bortskaffelse af skarpe genstande. 
• Sharps disposal container.
I PsA-studie 2 var andelen af patienter, der opnåede et modificeret PsA Response Criteria (PsARC)respons højere blandt patienter behandlet med secukinumab (59,0 % og 61,0 % for henholdsvis 150 mg og 300 mg) sammenlignet med placebo (26,5 %) ved uge 24. 
In PsA study 2, the proportion of patients achieving a modified PsA Response Criteria (PsARC) response was greater in the secukinumab-treated patients (59.0% and 61.0% for 150 mg and 300 mg, respectively) compared to placebo (26.5%) at week 24.
Ved uge 16 og uge 52 blev der påvist statistisk signifikante forbedringer (CLEAR) i patientrapporterede tegn og symptomer på kløe, smerte og afskalning i Psoriasis Symptom Diary© 
Statistically significant improvements in patient-reported signs and symptoms of itching, pain and scaling at week 16 and week 52 (CLEAR) were demonstrated in the Psoriasis Symptom Diary©
Enkelt- og flerdosisfarmakokinetik af secukinumab hos patienter med plaque psoriasis blev påvist i flere studier med intravenøse doser varierende fra 1 x 0,3 mg/kg til 3 x 10 mg/kg og med subkutane doser varierende fra 1 x 25 mg til flere doser på 300 mg. Eksponering var dosisproportional på tværs af alle doseringsregimer. 
The single and multiple dose pharmacokinetics of secukinumab in plaque psoriasis patients were determined in several studies with intravenous doses ranging from 1x 0.3 mg/kg to 3x 10 mg/kg and with subcutaneous doses ranging from 1x 25 mg to multiple doses of 300 mg.
Hyppigheden af neutropeni i studier vedrørende psoriasisartrit og ankyloserende spondylitis svarer til hyppigheden ved psoriasis. 
The frequency of neutropenia in psoriatic arthritis and ankylosing spondylitis is similar to psoriasis.
Fordelen ved at bruge Cosentyx til plaque psoriasis er, at du får en afglatning af huden, og at det reducerer dine symptomer, fx afskalning, kløe og smerte. 
Using Cosentyx in plaque psoriasis will benefit you by leading to improvements of skin clearance and reducing your symptoms such as scaling, itching and pain.
Cosentyx indeholder det aktive stof secukinumab, der tilhører den lægemiddelgruppe, der kaldes interleukin-hæmmere (IL). 
Secukinumab is a monoclonal antibody which belongs to a group of medicines called interleukin (IL) inhibitors.
Secukinumab udviste større effekt sammenlignet med ustekinumab med hensyn til endepunkterne PASI 75/90/100-respons og IGA mod 2011 0- eller 1respons (”clear” eller ”almost clear”). 
Greater efficacy of secukinumab compared to ustekinumab for the endpoints PASI 75/90/100 and IGA mod 2011 0 or 1 response (“clear” or “almost clear”) was observed early and continued through to week 52.
Dette blev vurderet ud fra en signifikant forbedring i forhold til baseline i både PSSI 90 respons (52,9% versus 2,0%) og IGA mod 2011 0 eller 1 (kun hovedbund) respons (56,9% versus 5,9%). 
Secukinumab 300 mg was superior to placebo at week 12 as assessed by significant improvement from baseline in both the PSSI 90 response (52.9% versus 2.0%) and IGA mod 2011 0 or 1 scalp only response (56.9% versus 5.9%).
Anvisninger til brug af Cosentyx-pulver til injektionsvæske, opløsning 
Instructions for use of Cosentyx powder for solution for injection
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen eller hætteglasset efter EXP. 
Do not use this medicine after the expiry date which is stated on the outer box or vial after “EXP”.
Der er rapporteret ikke-alvorlige mukokutane candidainfektioner med relation til virkningsmekanismen for secukinumab for secukinumab mere hyppigt end placebo i psoriasis kliniske studier (3,55 per 100 patientår for secukinumab 300 mg mod 1.00 per 100 patientår for placebo) (se pkt. 
Related to the mechanism of action of secukinumab, non-serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies (3.55 per 100 patient years for secukinumab 300 mg versus 1.00 per 100 patient years for placebo) (see section 4.8).
Af de 72 patienter, der var randomiseret til secukinumab 150 mg, havde henholdsvis 45 og 35 et ASAS 20/40-respons. 
Of the 72 patients randomised to secukinumab 150 mg, 45 and 35 had an ASAS 20/40 response, respectively.
For instruktioner om rekonstitution af lægemidlet før administration, se pkt. 
For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the Instructions for Use in the package leaflet.
LÆS DETTE, FØR DU BEGYNDER 
YOU MUST READ THIS BEFORE INJECTING.
I de sidste 3 tilfælde, blev der rapporteret ikke-alvorlige infektioner med sædvanlig respons på standardbehandling og krævede ikke seponering af secukinumab. 
Non-serious infections with usual response to standard care and not requiring discontinuation of secukinumab were reported in the remaining 3 cases.
AS-studie 1 (MEASURE 1) evaluerede 371 patienter, hvoraf henholdsvis 14,8 % og 33,4 % fik samtidig MTX eller sulfasalazin. 
AS study 1 (MEASURE 1) evaluated 371 patients, of whom 14.8% and 33.4% used concomitant MTX or sulfasalazine, respectively.
AS-studie 2 (MEASURE 2) evaluerede 219 patienter, hvoraf henholdsvis 11,9 % og 14,2 % fik samtidig MTX eller sulfasalazin. 
AS study 2 (MEASURE 2) evaluated 219 patients, of whom 11.9% and 14.2% used concomitant MTX or sulfasalazine, respectively.
Lad være med at gnide på det. 
Do not shake.
Den aftagelige kanylehætte på Cosentyx fyldt injektionssprøjte indeholder et derivat af naturgummilatex. 
The removable needle cap of the Cosentyx pre-filled syringe contains a derivative of natural rubber latex.
Af de 100 patienter, der var randomiseret til secukinumab 300 mg, havde henholdsvis 64, 44 og 24 ACR20/50/70-respons. 
Of the 100 patients randomised to secukinumab 300 mg, 64, 44 and 24 had an ACR 20/50/70 response, respectively.
ASAS 20-respons var forbedret ved uge 16 hos både anti-TNFα-naive patienter (68,2 % versus 31,1 %; p<0,05) og anti-TNFα-IR-patienter (50,0 % versus 24,1 %; p<0,05) for secukinumab 150 mg sammenlignet med placebo. 
ASAS 20 responses were improved at week 16 in both anti-TNFα-naïve patients (68.2% versus 31.1%; p<0.05) and anti-TNFα-IR patients (50.0% versus 24.1%; p<0.05) for secukinumab 150 mg compared with placebo, respectively.
Den fyldte injektionssprøjte i pennen er en 1 ml glassprøjte med en silikone-coatet bromobutyl-gummistempelprop, fast 27G x ½" kanyle og fast kanyleskjold af styrenbutadiengummi. 
The pre-filled syringe inside the pen is a 1 ml glass syringe with a silicone-coated bromobutyl rubber plunger stopper, staked 27G x ½″ needle and rigid needle shield of styrene butadiene rubber.
• hvis væsken indeholder umiddelbart synlige partikler, er uklar eller tydeligt brun. 
• if the liquid contains easily visible particles, is cloudy or is distinctly brown.
I kliniske studier er der observeret infektioner hos patienter, der behandles med secukinumab (se pkt. 
In clinical studies, infections have been observed in patients receiving secukinumab (see section 4.8).
PASI 100-respons n (%) 2 (0,8 %) 31 
PASI 100 response n (%) 2 (0.8%) 31
Din Cosentyx SensoReady-pen: 
Your Cosentyx SensoReady pen:
I både studie 1 og studie 2 blev patienter, der var randomiseret til at få placebo og var ikke-responderende ved uge 12, derefter skiftet over til secukinumab (enten 150 mg eller 300 mg) i ugerne 12, 13, 14 og 15, fulgt af samme dosis hver måned med start i uge 16. 
In both study 1 and study 2, patients randomised to receive placebo who were non-responders at week 12 then crossed over to receive secukinumab (either 150 mg or 300 mg) at weeks 12, 13, 14, and 15, followed by the same dose every month starting at week 16.
• hvis du bruger anden medicin eller har gjort det for nylig, og 
• if you are taking, have recently taken or might take any other medicines.
Lad hætteglasset stå ved stuetemperatur i ca. 5 minutter uden at røre det. 
Allow the vial to stand undisturbed at room temperature for approximately 5 minutes.
Før opløsning: Opbevar hætteglasset i køleskab ved en temperatur mellem 2 °C - 8 °C. 
Before reconstitution: Store the vial in the refrigerator between 2°C and 8°C.
Af de 100 patienter, der var randomiseret til secukinumab 150 mg, havde henholdsvis 64, 39 og 20 ACR20/50/70 respons. 
Of the 100 patients randomised to secukinumab 150 mg, 64, 39 and 20 had an ACR 20/50/70 response, respectively.
Patienterne blev randomiseret til 150 mg eller 300 mg secukinumab eller placebo subkutant ved uge 0, 1, 2, 3 og 4, efterfulgt af samme dosis hver måned eller en månedlig injektion af 150 mg secukinumab (uden loading). 
Patients were randomised to receive secukinumab 150 mg, 300 mg or placebo subcutaneously at weeks 0, 1, 2, 3 and 4, followed by the same dose every month, or a once monthly injection of secukinumab 150 mg (without loading).
Ved uge 12 blev der påvist statistisk signifikante forbedringer (formindskelse) fra baseline sammenlignet med placebo i patientrapporterede tegn og symptomer på kløe, smerte og afskalning i studiet med patienter, som har psoriasis i hovedbunden. 
Statistically significant improvements (decreases) at week 12 from baseline in the scalp psoriasis study were demonstrated in patient reported signs and symptoms of scalp itching, pain and scaling compared to placebo.
Dactylitis-ophør n (%) † 
Dactylitis resolution n (%) † Week 16
indeholder 150 mg secukinumab. 
150 mg secukinumab.
Pakning indeholder 2 fyldte penne 
Pack containing 2 pre-filled pens
- Øvrige indholdsstoffer: trehalosedihydrat, histidin, histidinhydrochloridmonohydrat, methionin, 
- The other ingredients are trehalose dihydrate, histidine, histidine hydrochloride monohydrate,
Brug ikke injektionssprøjten efter den udløbsdato, der står på yderpakningen eller på injektionssprøjtens etiket efter ”Udløbsdato” eller ”EXP”. 
Do not use the syringe after the expiry date which is stated on the outer box or syringe label after “EXP”.
* Patienter behandlet med secukinumab fik en dosis på 300 mg ved uge 0, 1, 2, 3 og 4, efterfulgt af samme dosis hver 4. uge indtil uge 52. 
* Patients treated with secukinumab received 300 mg doses at weeks 0, 1, 2, 3 and 4, followed by the same dose every 4 weeks until week 52.
Secukinumabs sikkerhed og virkning er blevet evalueret hos 1.999 patienter i tre randomiserede, dobbeltblinde, placebokontrollerede fase III-studier hos patienter med aktiv psoriasisartrit (≥3 hævede og ≥3 ømme led) trods behandling med non-steroidt anti-inflammatorisk lægemiddel (NSAID), kortikosteroid eller sygdomsmodificerende antireumatikum (DMARD). 
The safety and efficacy of secukinumab were assessed in 1,999 patients in three randomised, double-blind, placebo-controlled phase III studies in patients with active psoriatic arthritis (≥3 swollen and ≥3 tender joints) despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid or disease-modifying anti-rheumatic drug (DMARD) therapy.
Hætteglassene er kun til engangsbrug. 
Vials are for single use only.
I PsA-studie 3 var det procentvise antal patienter uden sygdomsprogression (defineret som mTSS ændring fra baseline ≤0,5) fra randomisering til uge 24 henholdsvis 80,3 %, 88,5 % og 73,6 % for secukinumab 150 mg, 300 mg og placebo. 
In PsA study 3, the percentage of patients with no disease progression (defined as a change from baseline in mTSS of ≤0.5) from randomisation to week 24 was 80.3%, 88.5% and 73.6% for secukinumab 150 mg, 300 mg and placebo, respectively.
Antal patienter med psoriasisafficeret hud ≥3 % af BSA ved baseline PASI 75-respons n (%) 
Number of patients with ≥3% BSA psoriasis skin involvement at baseline
• Den anbefalede dosis er 300 mg som indsprøjtning under huden (subkutan injektion). 
• The recommended dose is 300 mg by subcutaneous injection.
Det procentvise antal patienter uden sygdomsprogression fra uge 24 til uge 52 var 85,7 % for patienter, der fik secukinumab 10 mg/kg intravenøs initialdosis, efterfulgt af 150 mg subkutan vedligeholdelsesbehandling, og 86,8 % for patienter behandlet med placebo, som skiftede til 75 mg eller 150 mg subkutan administation hver 4. uge ved uge 16 eller uge 24. 
The percentage of patients with no disease progression from week 24 to week 52 for secukinumab 10 mg/kg intravenous load - followed by 150 mg subcutaneous maintenance and for placebo patients who switched to 75 mg or 150 mg subcutaneous every 4 weeks at week 16 or week 24 was 85.7% and 86.8%, respectively.
Secukinumabs sikkerhed og virkning er blevet evalueret hos 816 patienter i tre randomiserede, dobbeltblinde, placebokontrollerede fase III-studier hos patienter med aktiv ankyloserende spondylitis (AS) med et Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-indeks ≥4 trods behandling med non-steroidt anti-inflammatorisk lægemiddel (NSAID), kortikosteroid eller sygdomsmodificerende antireumatikum (DMARD). 
The safety and efficacy of secukinumab were assessed in 816 patients in three randomised, double-blind, placebo-controlled phase III studies in patients with active ankylosing spondylitis (AS) with a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid or disease-modifying anti-rheumatic drug (DMARD) therapy.
AS-studie 3 (MEASURE 3) evaluerede 226 patienter, hvoraf henholdsvis 13,3 % og 23,5 % fik samtidig MTX eller sulfasalazin. 
AS study 3 (MEASURE 3) evaluated 226 patients, of whom 13.3% and 23.5% used concomitant MTX or sulfasalazine, respectively.
Cosentyx 150 mg pulver til injektionsvæske, opløsning skal klargøres af sundhedspersonale. 
Cosentyx 150 mg powder for solution for injection must be prepared by a healthcare professional.
I PsA-studie 2, havde både anti-TNFα-naive og anti-TNFα-IR-patienter behandlet med secukinumab et signifikant højere ACR20-respons sammenlignet med placebo ved uge 24, med et lidt højere respons hos anti-TNFα-naive patienter (anti-TNFα-naive: 64 % og 58 % for henholdsvis 150 mg og 300 mg sammenlignet med placebo 15,9 %; anti-TNFα-IR: 30 % og 46 % for henholdsvis 150 mg og 300 mg sammenlignet med placebo 14,3 %). 
In PsA study 2, both anti-TNFα-naive and anti-TNFα-IR secukinumab-treated patients had a significantly higher ACR 20 response compared to placebo at week 24, with a slightly higher response in the anti-TNFα-naive group (anti-TNFα-naive: 64% and 58% for 150 mg and 300 mg, respectively, compared to placebo 15.9%; anti-TNFα-IR: 30% and 46% for 150 mg and 300 mg, respectively, compared to placebo 14.3%).
Patienter behandlet med secukinumab uden samtidig behandling med MTX havde et højere ACR20-respons (53,6 % og 53,6 % for henholdsvis 150 mg og 300 mg) sammenlignet med placebo (10,4 %) og ACR50-respons (37,5 % og 32,1 % for henholdsvis 150 mg og 300 mg) sammenlignet med placebo (6,3 %). 
Secukinumab-treated patients without concomitant MTX use had a higher ACR 20 response (53.6% and 53.6% for 150 mg and 300 mg, respectively, compared to placebo 10.4%) and ACR 50 response (37.5% and 32.1% for 150 mg and 300 mg, respectively, compared to placebo 6.3%).
Medicinen må ikke anvendes, hvis du opdager, at pulveret ikke er helt opløst, eller hvis injektionsvæsken indeholder tydeligt synlige partikler, er uklar eller er tydeligt brun. 
Do not use this medicine if you notice that the powder has not fully dissolved or if the liquid contains easily visible particles, is cloudy or is distinctly brown.
1 fyldt injektionssprøjte 2 fyldte injektionssprøjter 
1 pre-filled syringe 2 pre-filled syringes
Cosentyx bruges til voksne med aktiv gigt i rygsøjlen. 
Cosentyx is used in adults with active ankylosing spondylitis.
Der blev ikke observeret interaktioner mellem secukinumab og midazolam (CYP3A4-substrat) i et studie med patienter med plaque psoriasis. 
In a study in subjects with plaque psoriasis, no interaction was observed between secukinumab and midazolam (CYP3A4 substrate).
KARTON - hætteglas 
CARTON - vial
Cosentyx pulver til injektionsvæske, opløsning, er et hvidt, fast pulver i et hætteglas. 
What Cosentyx looks like and contents of the pack Cosentyx powder for solution for injection is a white solid powder in a glass vial.
I PsA-studie 1 var det procentvise antal patienter uden sygdomsprogression (defineret som ændring i mTSS på ≤0,5 i forhold til baseline) fra randomisering til uge 24 82,3 % for secukinumab 10 mg/kg intravenøs initialdosis og 150 mg subkutan vedligeholdelsesdosis og 75,7 % for placebo. 
In PsA study 1, the percentage of patients with no disease progression (defined as a change from baseline in mTSS of ≤0.5) from randomisation to week 24 was 82.3% in secukinumab 10 mg/kg intravenous load - 150 mg subcutaneous maintenance and 75.7% in placebo.